6UGV

Crystal structure of the Fab fragment of anti-TNFa antibody infliximab (Remicade) in a I-centered orthorhombic crystal form, Lot C

Summary for 6UGV

• Entry DOI: 10.2210/pdb6ugv/pdb
• Descriptor: Infliximab Fab Heavy Chain, Infliximab Fab Light Chain, MESO-ERYTHRITOL, ... (5 entities in total)
• Functional Keywords: antibody, fab, infliximab, biosimilar, tnfa, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 4
• Total formula weight: 96064.55

Authors

Lerch, T.F.,Sharpe, P.,Mayclin, S.J.,Edwards, T.E.,Polleck, S.,Rouse, J.C.,Conlan, H.D. (deposition date: 2019-09-26, release date: 2019-11-13, Last modification date: 2024-11-06)

Primary citation

Lerch, T.F.,Sharpe, P.,Mayclin, S.J.,Edwards, T.E.,Polleck, S.,Rouse, J.C.,Zou, Q.,Conlon, H.D.
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.
BioDrugs, 34:77-87, 2020

PubMed Abstract: Higher-order structure (HOS) assessment is an important component of biosimilarity evaluations. While established spectroscopic methods are routinely used to characterize structure and evaluate similarity, the addition of X-ray crystallographic analysis to these biophysical methods enables orthogonal elucidation of HOS at higher resolution.

PubMed: 31650490
DOI: 10.1007/s40259-019-00390-1

Experimental method

X-RAY DIFFRACTION (2.4 Å)